Related Experiment Video
Updated: Apr 7, 2026
A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
Targeting neutrophil-driven inflammation in bronchopulmonary dysplasia: From pathogenesis to therapeutic perspectives
Maria Giulia Conti1, Rebecca Morelli1, Elvira Mazzuca1
1Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, viale Regina Elena 324, 00161 Rome, Italy.
Insights
Neutrophil inflammation drives chronic lung disease in preterm infants (bronchopulmonary dysplasia). Targeting neutrophils may offer early risk prediction and new therapies for this condition.
Area of Science:
- Neonatal immunology
- Pulmonary medicine
- Inflammatory diseases
Background:
- Neutrophil-driven inflammation is central to bronchopulmonary dysplasia (BPD) pathogenesis in preterm infants.
- Neutrophils contribute to impaired alveolarization and lung function deficits in BPD.
- Preclinical models demonstrate a causal link between neutrophil activation and neonatal lung injury.
Purpose of the Study:
- To explore the role of neutrophils in BPD.
- To identify neutrophil-related biomarkers for early risk stratification and intervention.
- To assess the potential for anti-neutrophilic therapies in BPD.
Main Methods:
- Review of preclinical hyperoxia models in neonatal mice.
- Analysis of emerging neutrophil-related biomarkers, including neutrophil-to-lymphocyte ratio.
- Discussion of clinical translation challenges and future research directions.
Main Results:
- Neutrophil activation is causally linked to lung injury in neonatal hyperoxia models.
- Neutrophil-to-lymphocyte ratio shows potential as a predictive biomarker for BPD onset and severity.
- Clinical translation of targeted therapies remains limited despite promising preclinical data.
Conclusions:
- Neutrophil modulation is a key therapeutic target for BPD.
- Further research is needed to validate neutrophil biomarkers and phenotypes.
- Clinical trials evaluating anti-neutrophilic therapies are warranted for neonates with BPD.
Abstract:
Neutrophil-driven inflammation plays a key role in the initiation and progression of the chronic lung disease of preterm infants, also known as bronchopulmonary dysplasia (BPD). Their modulation represents a promising avenue for early risk stratification and targeted intervention. Among its pathogenic mechanisms, neutrophils are central contributors to impaired alveolarization and lung function defects. Preclinical hyperoxia models in neonatal mice confirm a causal link between neutrophil activation and lung injury. Early neutrophil-related biomarkers such as blood neutrophil to lymphocyte ratio are emerging as predictive of BPD onset and severity. Despite these findings, clinical translation in targeted therapies remains limited. Further research should focus on validating neutrophil-derived biomarkers, characterizing neutrophil phenotypes, and ultimately propose clinical trials to evaluate the safety and efficacy of anti-neutrophilic anti-inflammatory therapies in neonates.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:38Inflammation
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:29Pneumonia II: Pathophysiology
01:17Pulmonary Cycle: Exhalation